Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients

Michele B. Kaufman, PharmD, BCGP  |  April 20, 2016

Clinical trials have begun to determine if disodium zoledronate tetrahydrate is safe and effective for treating pain in patients with knee osteoarthritis. The FDA has approved the use of ixekizumab for the treatment of plaque psoriasis. And a study has shown that patients with SLE treated with belimumab may be able to decrease steroid use…

CMS Commences 45-Day Open Payments Review & Dispute Period

From the College  |  April 18, 2016

On April 1, the Centers for Medicare and Medicaid Services (CMS) announced the beginning of the 45-day Open Payments Review and dispute period, which will conclude on May 15. After the review period concludes, on June 30, CMS will publish 2015 payment data along with updates to the 2013 and 2014 data. If you are…

Platelet-Rich Plasma Therapy May Treat Degenerative Tendinopathies & Pain

Lara C. Pullen, PhD  |  April 18, 2016

A recent small-scale study showed that patients who received platelet-rich plasma therapy for tendon healing experienced clinically important improvements in pain and disability compared with placebo. Additionally, MRI showed that some participants had improvement in the pathoanatomy of the rotator cuff six months after treatment…

2015 ACR/ARHP Annual Meeting: Global Challenges in Rheumatic Disease Care

Thomas R. Collins  |  April 15, 2016

SAN FRANCISCO—To convey the plight of rheumatology patients in sub-Saharan Africa, Girish Mody, MD, head of rheumatology at the University of KwaZulu-Natal in South Africa and past president of the African League of Associations for Rheumatology, recounted a story during the 2015 ACR/ARHP Annual Meeting from the World Health Organization about a diabetes patient. The…

Sifalimumab Shows Some Promise Against Lupus

Reuters Staff  |  April 15, 2016

NEW YORK (Reuters Health)—Sifalimumab, an anti-interferon alpha monoclonal antibody, may lead to some improvement in patients with systemic lupus erythematosus (SLE), according to a new trial. In a paper online on March 23 in Annals of the Rheumatic Diseases, Dr. Munther Khamashta of King’s College London and colleagues note that treatment of SLE presents a…

The Microbiome in Pediatric Rheumatic Diseases

The Microbiome in Pediatric Rheumatic Diseases

Matthew Stoll, MD, PhD  |  April 15, 2016

The human intestinal microbiota is home to more than 1,000 bacterial species, containing approximately 3 million genes, many of which code for functions that have the potential to affect human physiology.1 Smaller numbers of organisms are also present in the skin, upper gastrointestinal tract, female reproductive tract and the oro- and nasopharynx. As tools have…

Technological Advances Linked to Medical Misadventures

Simon M. Helfgott, MD  |  April 15, 2016

For keen students of American politics, the unending intrigue of the 2016 presidential race has been riveting. With an assemblage of aspiring candidates that, at its start, included a bevy of U.S. senators and former governors, a media-savvy real estate mogul, a renowned Hopkins neurosurgeon and an ophthalmologist, political junkies among us have feasted on…

Practicing Mindfulness Can Help Alter Patients’ Experience With Chronic Rheumatic Diseases

Practicing Mindfulness Can Help Alter Patients’ Experience with Chronic Rheumatic Diseases

C. Ronald MacKenzie, MD  |  April 15, 2016

Mindfulness is a mental state achieved by focusing one’s awareness on the present moment, while acknowledging and non-judgmentally accepting one’s feelings, thoughts and bodily sensations. Known in Sanskrit as smrti, meaning “to remember,” in Pali, the language of early Buddhist scriptures, it is recognized by the word sati (mindfulness).1 Derived from ancient meditative Buddhist disciplines,…

Medicare Access and CHIP Reauthorization Act of 2015: What You Should Know

Joan M. Von Feldt, MD, MSEd, FACR, FACP  |  April 15, 2016

There is no denying that the past few years have been a time of immense change in healthcare. Sweeping pieces of legislation have fundamentally altered the way we practice medicine. This is absolutely the case when it comes to the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA, for short). MACRA is an enormous…

Rheumatology Research Foundation Creates Five-Year Strategic Plan

From the College  |  April 15, 2016

Dramatic advancements in research toward prevention and cure are at risk, as federal research funding for rheumatic diseases has declined by 40% over the past five years. With that, an alarming number of rheumatologists are preparing for retirement. To stop this worrying trend, a strategic plan for the next five years was developed to complement…

  • « Previous Page
  • 1
  • …
  • 507
  • 508
  • 509
  • 510
  • 511
  • …
  • 814
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences